BACKGROUND: Both increased age and type 2 diabetes mellitus are risk factors for developing bone fractures. While recent data in the elderly suggest a link between hypoglycemia and fall-related fractures, the association between sulfonylureas, commonly used hypoglycemic agents, and fracture risk has not been well investigated. METHODS: We used patient data from a large commercial health insurer from 2002-2005. Individuals aged ≥65 years receiving oral sulfonylurea treatment (n=13,195) were matched 1:1 to non-users based on propensity for sulfonylurea use. Multivariable conditional logistic regression was used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (CIs). RESULTS: During an average 4 years of follow-up, sulfonylurea users experienced 226 incident hip fractures (1.7%) and non-users experienced 157 (1.2%). Sulfonylurea use was associated with increased risk of developing hip fracture (aOR 1.46, 95% CI 1.17-1.82), and this association was apparent for men (120 cases; aOR 1.83, 95% CI 1.25-2.66) and women (263 cases; aOR 1.32, 95% CI 1.03-1.69). Patients with documented hypoglycemia in the follow-up period had increased odds of hip fracture relative to those without such diagnosis (aOR 2.42, 95% CI 1.35-4.34). CONCLUSION: Sulfonylureas are associated with increased risk of hip fracture in elderly men and women with type 2 diabetes.
BACKGROUND: Both increased age and type 2 diabetes mellitus are risk factors for developing bone fractures. While recent data in the elderly suggest a link between hypoglycemia and fall-related fractures, the association between sulfonylureas, commonly used hypoglycemic agents, and fracture risk has not been well investigated. METHODS: We used patient data from a large commercial health insurer from 2002-2005. Individuals aged ≥65 years receiving oral sulfonylurea treatment (n=13,195) were matched 1:1 to non-users based on propensity for sulfonylurea use. Multivariable conditional logistic regression was used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (CIs). RESULTS: During an average 4 years of follow-up, sulfonylurea users experienced 226 incident hip fractures (1.7%) and non-users experienced 157 (1.2%). Sulfonylurea use was associated with increased risk of developing hip fracture (aOR 1.46, 95% CI 1.17-1.82), and this association was apparent for men (120 cases; aOR 1.83, 95% CI 1.25-2.66) and women (263 cases; aOR 1.32, 95% CI 1.03-1.69). Patients with documented hypoglycemia in the follow-up period had increased odds of hip fracture relative to those without such diagnosis (aOR 2.42, 95% CI 1.35-4.34). CONCLUSION:Sulfonylureas are associated with increased risk of hip fracture in elderly men and women with type 2 diabetes.
Authors: Lucas E Nikkel; Edward J Fox; Kevin P Black; Charles Davis; Lucille Andersen; Christopher S Hollenbeak Journal: J Bone Joint Surg Am Date: 2012-01-04 Impact factor: 5.284
Authors: Bowen Wang; Zehai Wang; Atharva A Poundarik; Mohammed J Zaki; Richard S Bockman; Benjamin S Glicksberg; Girish N Nadkarni; Deepak Vashishth Journal: J Clin Endocrinol Metab Date: 2022-03-24 Impact factor: 5.958
Authors: E Losada; B Soldevila; M S Ali; D Martínez-Laguna; X Nogués; M Puig-Domingo; A Díez-Pérez; D Mauricio; D Prieto-Alhambra Journal: Osteoporos Int Date: 2018-06-02 Impact factor: 4.507
Authors: Labib Al-Musawe; Carla Torre; Jose Pedro Guerreiro; Antonio Teixeira Rodrigues; Joao Filipe Raposo; Helder Mota-Filipe; Ana Paula Martins Journal: Pharmacol Res Perspect Date: 2020-08